Faculty Profiles - TAKAHASHI, Yoshiyuki

Papers - TAKAHASHI, Yoshiyuki

Division display 121 - 140 of about 483 ／ All the affair displays >>

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma. International journal Open Access

Masayuki Imaya, Hideki Muramatsu, Atsushi Narita, Ayako Yamamori, Manabu Wakamatsu, Taro Yoshida, Shunsuke Miwata, Kotaro Narita, Daisuke Ichikawa, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Nobuhiro Nishio, Seiji Kojima, Yoshiyuki Takahashi

Cancer medicine Vol. 11 ( 9 ) page： 1956 - 1964 2022.5

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Patients with primary refractory and relapsed neuroblastoma have a poor prognosis since safe and effective chemotherapies for these patients are currently limited. The development of new chemotherapy regimens for these patients is imperative to improve survival outcomes. METHODS: We retrospectively analyzed 40 patients with refractory (n = 36) or relapsed (n = 4) neuroblastoma who received irinotecan, etoposide, and carboplatin (IREC) as a second-line treatment. We evaluated their therapeutic response and the toxicity of IREC. We also assessed the impact of UGT1A1 gene polymorphisms, which are involved in irinotecan metabolism, on outcomes and toxicity. RESULTS: A total of 112 cycles of IREC were administered to 40 patients with a median of 2 cycles per patient (range, 1-9). Six (15%) patients (UGT1A1 wild-type [n = 2] and heterozygous [n = 4]) showed objective responses, including partial response (n = 1), tumor shrinkage (n = 4), and improved findings on their MIBG scan (n = 1). Grade 4 neutropenia, grade 4 leukopenia, and grades 3-4 gastrointestinal toxicity were observed in 110 (98%), 88 (79%), and 3 (3%) cycles, respectively. There was no IREC-related mortality. Patients with UGT1A1 polymorphisms showed a higher frequency of grade 4 leukopenia, but these patients did not have increased treatment-related mortality or non-hematologic toxicity. CONCLUSIONS: IREC showed an objective response rate of 15% including 1 case with partial response. IREC was well tolerated regardless of UGT1A1 genotype. This study suggests that IREC is a promising second-line chemotherapy for refractory or relapsed neuroblastoma.

DOI： 10.1002/cam4.4529

Web of Science

PubMed

Predictive factors of acute respiratory events during initial induction chemotherapy in patients with advanced neuroblastoma Open Access

Matsui, M; Makimoto, A; Nishio, N; Takahashi, Y; Urashima, M; Yuza, Y

CANCER REPORTS Vol. 5 ( 5 ) page： e1499 2022.5

脊髄圧迫によるoncologic emergencyを呈した大腰筋内の後腹膜腫瘍

片岡伸介, 佐治木大知, 津村悠介, 前村遼, 今屋雅之, 山森彩子, 若松学, 谷口理恵子, 濱田太立, 西川英里, 川島希, 成田敦, 村松秀城, 西尾信博, 高橋義行, 内田広夫, 中川洋一, 田井中貴久, 安井昭洋, 中黒匡人, 下山芳江

日本小児血液・がん学会雑誌 Vol. 59 ( 1 ) page： 72 - 72 2022.5

Minor PNH clones do not distinguish inherited bone marrow failure syndromes from immune-mediated aplastic anemia. International journal Open Access

Atsushi Narita, Shunsuke Miwata, Masayuki Imaya, Yusuke Tsumura, Ayako Yamamori, Manabu Wakamatsu, Motoharu Hamada, Rieko Taniguchi, Yusuke Okuno, Hideki Muramatsu, Yoshiyuki Takahashi

Blood advances Vol. 6 ( 8 ) page： 2517 - 2519 2022.4

Death review of children receiving medical care at home. International journal Open Access

Jun Natsume, Atsushi Numaguchi, Atsuko Ohno, Mihoko Mizuno, Yoshiyuki Takahashi, Akihisa Okumura, Tetsushi Yoshikawa, Shinji Saitoh, Kiyokuni Miura, Masaharu Noda

Pediatric research Vol. 91 ( 5 ) page： 1286 - 1289 2022.4

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Children receiving home medical care need special attention to prevent unexpected death. The aim of this study was to clarify the factors contributing to death in children receiving home medical care from the child death review database. METHODS: Children receiving home medical care were enrolled from the child death review database from 2014 to 2016 in Aichi prefecture, Japan, with a population of one million children. Types of medical care and factors contributing to death were examined. RESULTS: Of the 631 children who died, 40 children (6%) were receiving home medical care (21: tracheostomy; 19: ventilator; 26: suctioning of naso-oral secretions; 19: oxygen inhalation; 32: tube feeding; 6: urethral catheterization; and 1: peritoneal dialysis). The death rate was 50 times that in the general population of children. Ten children had contributory factors that seemed to be preventable. In four children, the families could not replace the tracheostomy tubes during an accident. In three, oxygen saturation or ventilator alarms were not set appropriately. In two, an oxygen cylinder became empty. One child fell down from a seat in a car. CONCLUSIONS: Improvement of devices and correct guidance to caregivers may reduce the death rate in children receiving home medical care. IMPACT: Children receiving home medical care, such as tracheostomy care, mechanical ventilation, or tube feeding, need special attention to prevent unexpected death. In this population-based child death review, 6% of children received home medical care, and it was estimated that 1 of 100 children receiving home medical care died per year. One-quarter of the deaths could be preventable by caregiver education or development of devices.

DOI： 10.1038/s41390-021-01606-3

Open Access

Web of Science

PubMed

Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985-2016. International journal Open Access

Satoshi Miyamoto, Katsutsugu Umeda, Mio Kurata, Masakatsu Yanagimachi, Akihiro Iguchi, Yoji Sasahara, Keiko Okada, Takashi Koike, Reo Tanoshima, Masataka Ishimura, Masafumi Yamada, Maho Sato, Yoshiyuki Takahashi, Michiko Kajiwara, Hiroshi Kawaguchi, Masami Inoue, Yoshiko Hashii, Hiromasa Yabe, Koji Kato, Yoshiko Atsuta, Kohsuke Imai, Tomohiro Morio

Journal of clinical immunology Vol. 42 ( 3 ) page： 529 - 545 2022.4

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: Hematopoietic cell transplantation (HCT) is a curative therapy for most patients with inborn errors of immunity (IEI). We conducted a nationwide study on HCT for patients with IEI other than severe combined immunodeficiency (non-SCID) in Japan. METHODS: Data from the Japanese national database (Transplant Registry Unified Management Program, TRUMP) for 566 patients with non-SCID IEI, who underwent their first HCT between 1985 and 2016, were retrospectively analyzed. RESULTS: The 10-year overall survival (OS) and event-free survival (EFS) were 74% and 64%, respectively. The 10-year OS for HCT from unrelated bone marrow (URBM), accounting for 39% of HCTs, was comparable to that for HCT from matched sibling donor (MSD), 79% and 81%, respectively. HCT from unrelated cord blood (URCB), accounting for 28% of HCTs, was also common, with a 10-year OS of 69% but less robust engraftment. The intensity of conditioning was not associated with OS or neutrophil recovery; however, myeloablative conditioning was more frequently associated with infection-related death. Patients who received myeloablative irradiation showed poor OS. Multivariate analyses revealed that HCT in 1985-1995 (hazard ratio [HR], 2.0; P = 0.03), URCB (HR, 2.0; P = 0.01), and related donor other than MSD (ORD) (HR, 2.9; P < 0.001) were associated with poor OS, and URCB (HR, 3.6; P < 0.001) and ORD (HR, 2.7; P = 0.02) showed a higher incidence of retransplantation. CONCLUSIONS: We present the 1985-2016 status of HCT for non-SCID IEI in Japan with sufficient statistical power, highlighting the potential of URBM as an alternative donor and the feasibility of reduced intensity conditioning.

DOI： 10.1007/s10875-021-01199-w

Web of Science

PubMed

Genetic Study of Fanconi Anemia in Infancy Revealed FANCI Mutations and Defective ALDH2 Variant: A Case Report.

Urata T, Imamura T, Osone S, Muramatsu H, Takahashi Y, Hosoi H

Journal of pediatric hematology/oncology Vol. 44 ( 2 ) page： e438 - e441 2022.3

Short Report Nosocomial infection with rotavirus vaccine strain in paediatric patients with immunodeficiency

Miura, H; Taniguchi, K; Narita, K; Kawamura, Y; Kozawa, K; Muramatsu, H; Takahashi, Y; Ihira, M; Yoshikawa, T

JOURNAL OF HOSPITAL INFECTION Vol. 121 page： 9 - 13 2022.3

Prospective validation of the provisional entity of refractory cytopenia of childhood, proposed by the World Health Organization Open Access

Hama, A; Hasegawa, D; Manabe, A; Nozawa, K; Narita, A; Muramatsu, H; Kosaka, Y; Kobayashi, M; Koh, K; Takahashi, Y; Watanabe, K; Ohara, A; Ito, M; Kojima, S

BRITISH JOURNAL OF HAEMATOLOGY Vol. 196 ( 4 ) page： 1031 - 1039 2022.2

Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia Open Access

Tsuzuki, S; Yasuda, T; Kawazu, M; Ueno, T; Karnan, S; Ota, A; Sanada, M; Nagai, H; Tomita, A; Takahashi, Y; Miyazaki, Y; Matsumura, I; Kiyoi, H; Hosokawa, Y; Mano, H; Hayakawa, F

CANCER SCIENCE Vol. 113 page： 1236 - 1236 2022.2

Dyserythropoietic anaemia with an intronic GATA1 splicing mutation in patients suspected to have Diamond-Blackfan anaemia. International journal Open Access

Akie Kobayashi, Ryusei Ohtaka, Tsutomu Toki, Junichi Hara, Hideki Muramatsu, Rika Kanezaki, Yuka Takahashi, Tomohiko Sato, Takuya Kamio, Ko Kudo, Shinya Sasaki, Taro Yoshida, Taiju Utsugisawa, Hitoshi Kanno, Kenichi Yoshida, Yasuhito Nannya, Yoshiyuki Takahashi, Seiji Kojima, Satoru Miyano, Seishi Ogawa, Kiminori Terui, Etsuro Ito

EJHaem Vol. 3 ( 1 ) page： 163 - 167 2022.2

Language：English Publishing type：Research paper (scientific journal)

Diamond-Blackfan anaemia (DBA) shares clinical features with two recently reported sporadic cases of dyserythropoietic anaemia with a cryptic GATA1 splicing mutation (c.871-24 C>T). We hypothesized that some patients clinically diagnosed with DBA but whose causative genes were unknown may carry the intronic GATA1 mutation. Here, we examined 79 patients in our DBA cohort, who had no detectable causative genes. The intronic GATA1 mutation was identified in two male patients sharing the same pedigree that included multiple cases with anaemia. Cosegregation of this mutation and disease in multiple family members provide evidence to support the pathogenicity of the intronic GATA1 mutation.

DOI： 10.1002/jha2.374

Open Access

Web of Science

PubMed

胎児発育不全モデルラットの脳脊髄液中タンパク質の網羅的解析脳発達異常の病態解明に向けて

小野田淳人, 北瀬悠磨, 辻雅弘, 上田一仁, 高橋義行, 早川昌弘, 佐藤義朗

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 414 - 414 2022.2

投与経路に着目したMultilineage-differentiating stress enduring cell(Muse細胞)を用いた新生児慢性肺疾患の新規治療法開発

三浦良介, 佐藤義朗, 小野田淳人, 藤本健志, 後藤良子, 高本幸奈, 神澤孝洋, 鈴木紗記子, 上田一仁, 徐悦, 橋本佑樹, 落合加奈代, 谷口顕信, 田中龍一, 伊藤美春, 齊藤明子, 村松友佳子, 清水忍, 高橋義行, 早川昌弘

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 250 - 250 2022.2

TREC測定による新生児マススクリーニングにより診断され同種臍帯血移植を行ったX連鎖重症複合免疫不全症

山下大紀, 村松秀城, 今屋雅之, 山森彩子, 若松学, 片岡伸介, 濱田太立, 谷口理恵子, 川島希, 西川英里, 成田敦, 奥野友介, 西尾信博, 小島大英, 中島葉子, 柘植郁哉, 中村冨美子, 酒井好美, 伊藤哲哉, 高橋義行

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 281 - 281 2022.2

TREC測定による新生児マススクリーニングにより診断され同種臍帯血移植を行ったX連鎖重症複合免疫不全症

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 281 - 281 2022.2

New mimic of relapse or regional lymph node metastasis in a cancer survivor: a case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake Open Access

Tsumura, Y; Asakura, K; Takahashi, I; Akaihata, M; Takahashi, Y; Ishida, Y

IMMUNOLOGICAL MEDICINE Vol. 45 ( 1 ) page： 45 - 47 2022.1

Dorsal myelopathy after nelarabine and intrathecal methotrexate therapy

Sawamura, F; Natsume, J; Nakata, T; Muramatsu, H; Takahashi, Y

PEDIATRICS INTERNATIONAL Vol. 64 ( 1 ) page： e15334 2022.1

Conception by assisted reproductive technology in infants with critical congenital heart disease in Japan. Open Access

Morimoto Y, Go K, Yamamoto H, Fukasawa Y, Nakai M, Morihana E, Yasuda K, Nishikawa H, Ohashi N, Takahashi Y, Kato T

Reproductive biomedicine online Vol. 44 ( 1 ) page： 163 - 170 2022.1

Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation. International journal Open Access

Ryo Maemura, Manabu Wakamatsu, Kana Matsumoto, Hirotoshi Sakaguchi, Nao Yoshida, Asahito Hama, Taro Yoshida, Shunsuke Miwata, Hironobu Kitazawa, Kotaro Narita, Shinsuke Kataoka, Daisuke Ichikawa, Motoharu Hamada, Rieko Taniguchi, Kyogo Suzuki, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Yusuke Okuno, Nobuhiro Nishio, Koji Kato, Seiji Kojima, Kunihiko Morita, Hideki Muramatsu, Yoshiyuki Takahashi

Cell transplantation Vol. 31 page： 9636897221143364 - 9636897221143364 2022

Language：English Publishing type：Research paper (scientific journal)

Melphalan is widely used for hematopoietic stem cell transplantation (HSCT) conditioning. However, the relationship between its pharmacokinetic (PK) and transplantation outcomes in children has not been thoroughly investigated. We prospectively analyzed the relationship between melphalan area under the curve (AUC) and transplantation outcome and examined the development of a predictive model for melphalan clearance in children. This study included 43 children aged 0 to 19 years who underwent HSCT following a melphalan-based conditioning regimen from 2017 to 2021. In univariable analysis, high-melphalan AUC resulted in a significantly lower cumulative incidence of acute graft-versus-host disease and a higher cumulative incidence of thrombotic microangiopathy, although no significant difference was observed in survival. Regression analysis of a randomly selected derivation cohort (n = 21) revealed the following covariate PK model: predicted melphalan clearance (mL/min) = 6.47 × 24-h urinary creatinine excretion rate (CER, g/day) × 24-h creatinine clearance rate (CCR, mL/min) + 92.8. In the validation cohort (n = 22), the measured melphalan clearance values were significantly correlated with those calculated based on the prediction equation (R2 = 0.663). These results indicate that melphalan exposure may be optimized by adjusting the melphalan dose according to CER and CCR.

DOI： 10.1177/09636897221143364

Web of Science

PubMed

Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. International journal Open Access

Hironobu Kitazawa, Yusuke Okuno, Hideki Muramatsu, Kosuke Aoki, Norihiro Murakami, Manabu Wakamatsu, Kyogo Suzuki, Kotaro Narita, Shinsuke Kataoka, Daisuke Ichikawa, Motoharu Hamada, Rieko Taniguchi, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Nobuhiro Nishio, Asahito Hama, Mignon L Loh, Elliot Stieglitz, Seiji Kojima, Yoshiyuki Takahashi

Blood advances Vol. 5 ( 24 ) page： 5507 - 5518 2021.12

Language：English Publishing type：Research paper (scientific journal)

Juvenile myelomonocytic leukemia (JMML) is a rare myelodysplastic/myeloproliferative neoplasm that develops during infancy and early childhood. The array-based international consensus definition of DNA methylation has recently classified patients with JMML into the following 3 groups: high (HM), intermediate (IM), and low methylation (LM). To develop a simple and robust methylation clinical test, 137 patients with JMML were analyzed using the Digital Restriction Enzyme Analysis of Methylation (DREAM), which is a next-generation sequencing-based methylation analysis. Unsupervised consensus clustering of the discovery cohort (n = 99) using DREAM data identified HM (HM_DREAM; n = 35) and LM subgroups (LM_DREAM; n = 64). Of the 98 cases that could be compared with the international consensus classification, 90 HM (n = 30) and LM (n = 60) cases had 100% concordance with DREAM clustering results. Of the remaining 8 cases comprising the IM group, 4 were classified as belonging to the HM_DREAM group and 4 to the LM_DREAM group. A machine-learning classifier was successfully constructed using a support vector machine (SVM), which divided the validation cohort (n = 38) into HM (HM_SVM, n = 18) and LM (LM_SVM; n = 20) groups. Patients with the HM_SVM profile had a significantly poorer 5-year overall survival rate than those with the LM_SVM profile. In conclusion, we developed a robust methylation test using DREAM for patients with JMML. This simple and straightforward test can be easily incorporated into diagnosis to generate a methylation classification for patients so they can receive risk-adapted treatment in the context of future clinical trials.

DOI： 10.1182/bloodadvances.2021005080

Web of Science

PubMed

　 PREV - NEXT 　

<TAKAHASHI, Yoshiyuki>

Papers - TAKAHASHI, Yoshiyuki